NICE: Offer digital CBT to young people with mild depression

NICE |  January 2019 | Offer digital CBT to young people with mild depression, says NICE

Children and young people can be offered digital cognitive behavioural therapy (digital CBT, also known as computer CBT) as a first-line treatment for mild depression, says NICE. Currently digital CBT is recommended for adults with mild to moderate depression. 


NICE says that the choice of treatment should be based on clinical need and patient and carer preferences. The child or young person’s history, circumstances and maturity should also be considered.

Digital CBT is delivered on mobile phones, tablets or computers, meaning users can access help quickly, avoiding waiting lists.

This draft recommendation is made in a fast-tracked update to NICE’s existing guideline on depression in children and young people aged 5 to 18. It follows a recent trial (published in The Lancet)  which showed the benefits young people can gain from psychological therapies.

Digital CBT is already recommended for adults with mild to moderate depression (Source: NICE)

Read the full news story from NICE Offer digital CBT to young people with mild depression, NICE says 

See NICE Depression in children and young people: identification and management

See also:

The Lancet Cognitive behavioural therapy and short-term psychoanalytical psychotherapy versus a brief psychosocial intervention in adolescents with unipolar major depressive disorder (IMPACT): a multicentre, pragmatic, observer-blind, randomised controlled superiority trial 

[NICE Consultation] Intrapartum care for healthy women and babies

NICE | January 2019| Intrapartum care for healthy women and babies Clinical guideline [CG190]

A NICE consultation is open on Intrapartum care for healthy women and babies Clinical guideline [CG190]

This guideline covers the care of healthy women and their babies, during labour and immediately after the birth. It focuses on women who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women to make an informed choice about where to have their baby. It also aims to reduce variation in areas of care such as fetal monitoring during labour and management of the third stage of labour (NICE).

The consultation close on 22 January 2019

Details from NICE 

Hundreds more children and adults eligible for cochlear implants on the NHS

NICE| January 2019 | Hundreds more children and adults eligible for cochlear implants on the NHS

Following a review of the definition of severe to profound deafness which is used to identify if a cochlear implant might be appropriate, NICE have updated their eligibility criteria for cochlear implants. 

Meindert Boysen, director of the Centre for Technology Evaluation, said: “The appraisal committee listened to stakeholder concerns regarding the eligibility criteria for cochlear implants being out of date. Upon review it was concluded this needed to be updated.



“The new eligibility criteria for cochlear implants will ensure that they continue to be available on the NHS to those individuals who will benefit from them the most.”

Severe to profound deafness is now recognised as only hearing sounds louder than 80dB HL at 2 or more frequencies without hearing aids, a lowering of the previous threshold (Source: NICE).

NICE [press release]

Cochlear implants for children and adults with severe to profound deafness (part review of TA166)

See also:

Nursing Times  Hundreds more patients to be eligible for cochlear implants

The Independent NHS to offer hundreds more deaf people life-changing  cochlear implant 

Provisional thumbs up for drug to treat severe asthma

OnMedica | January 2018 | Provisional thumbs up for biological asthma drug

NICE have drafted guidance for an asthma drug for people who are unable to use inhalers, the drug called Benralizumab will be the third drug to be approved for people with severe eosinophilic asthma for NHS use by NICE. 

Mepolizumab was approved in December 2016 and reslizumab in October 2017. People who are eligible for mepolizumab or reslizumab can now be offered benralizumab (via OnMedica).

NICE recommends that when benralizumab and another biological treatment are deemed equally suitable for a patient, the cheapest option should be chosen first. Subject to any appeals, final guidance is scheduled for next month, and the NHS must make the drug available in England within three months of that date.

The full news story is available  from OnMedica

See NICE for full details